Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

ChemAxon Provides Chemistry Informatics Platform for the European Lead Factory

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
ChemAxon will provide the core tools to support the pan European initiative.

ChemAxon and the European Lead Factory have announced that ChemAxon will provide the core tools and leads the development of the informatics platform to support the pan European initiative.

ChemAxon will be building a portal to support the crowd-sourcing initiative using its core JChem Base and Marvin components.

The scientific decision process involved in selecting the right proposals from those submitted will be supported by ChemAxon’s Discovery Toolkit, including various fingerprints and physico-chemical property predictors.

The portal will also offer a way for submitters to keep track of their submission’s status and for the consortium’s selection committee to score and analyze submitted proposals.

The Innovative Medicines Initiative (IMI), the world’s largest public-private initiative in the field of pharmaceutical research aims to create a new and unique collaboration of public and private sector.

The research program of up to EUR196 million and named the European Lead Factory, involving small and medium-sized enterprises (SMEs), academic institutions and large pharmaceutical companies, aims to improve the competitiveness of the European pharmaceutical industry, accelerate the drug development process, and strives to develop safer, more effective drugs.

The European Lead Factory was launched by an international consortium of 30 partners, with the only Hungarian participant being ChemAxon Ltd. This partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates unprecedented opportunities for the discovery of new medicines through access to a collection of small molecules contributed by pharmaceutical companies, and a newly synthesized compound collection built by the SMEs and academic institutions.

As a result of this partnership, the new compound library consisting of up to half a million compounds will be accessible to all project partners and to public organizations.

Screening of this compound collection will be performed within the pharmaceutical companies and by a newly established European Screening Centre, which will run state of the art facilities in Scotland and the Netherlands to handle logistics and screening of compound libraries.

If the project proves successful during its initial five year funding period, the partnership aims for a sustainable role in drug discovery in Europe.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ChemAxon, BSSN Software Partner
ChemAxon and BSSN Software GmbH are announcing a partnership that allows users to manage analytical data in ChemAxon's chemistry software solutions using open standards.
Thursday, June 18, 2015
InnoCentive Integrates ChemAxon's Marvin JS
This move will enable the convenient drawing of chemical structures and reactions/reaction mechanisms in InnoCentive’s innovation management software platform.
Friday, June 05, 2015
Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
Leading pharmaceutical company continues the trend of building future cheminformatics platforms on ChemAxon technology.
Friday, February 15, 2013
ChemAxon Extends Free Service with Predicted Data and User Customization
The new features help users understand better the chemical structure with more predicted properties and a customizable layout.
Monday, August 23, 2010
Broad Institute Acquires License to all ChemAxon Products and Deploys Across Chemical Biology Platform
License covers ChemAxon’s platform, discovery toolkits and desktop applications for institute-wide use.
Friday, August 20, 2010
ChemAxon Announces new CEO and Head of R&D
Company increases its focus on business development and market position with new appointments.
Tuesday, May 13, 2008
Migrating Chemical Information to New Architectures
New ChemAxon whitepaper discusses the drivers behind the increasing number of pharma and biotech companies moving from traditional proprietary chemical information systems to modern alternatives.
Monday, January 29, 2007
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos